Nanocurcumin ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1
271	強直性脊椎炎	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03150966 (ClinicalTrials.gov)	June 8, 2016	6/5/2017	The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients	The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients	Multiple Sclerosis	Drug: Nanocurcumin;Drug: Placebo	Tabriz University of Medical Sciences	NULL	Completed	18 Years	65 Years	All	41	Phase 2	Iran, Islamic Republic of

271. 強直性脊椎炎

---

臨床試験数 : 563 /  薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03140657 (ClinicalTrials.gov)	April 29, 2017	28/4/2017	The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients	The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Ankylosing Spondylitis Patients	Ankylosing Spondylitis	Drug: Nanocurcumin;Drug: Placebo	Tabriz University of Medical Sciences	NULL	Completed	23 Years	46 Years	All	24	Phase 2	Iran, Islamic Republic of